{
    "clinical_study": {
        "@rank": "105745", 
        "arm_group": {
            "arm_group_label": "Diagnostic (MRI)", 
            "arm_group_type": "Experimental", 
            "description": "Patients undergo MRI scans for LV function, T1 myocardial signal, and aortic PWV at baseline, 3 months, and 24 months."
        }, 
        "brief_summary": {
            "textblock": "This trial studies how well magnetic resonance imaging (MRI) works in detecting heart damage\n      in patients with cancer receiving chemotherapy. Diagnostic procedures, such as MRI, may help\n      doctors predict whether patients will have heart damage caused by chemotherapy in patients\n      with cancer receiving chemotherapy."
        }, 
        "brief_title": "MRI in Detecting Heart Damage in Patients With Cancer Receiving Chemotherapy", 
        "condition": [
            "Cardiac Toxicity", 
            "Malignant Neoplasm"
        ], 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To design an automated MRI hardware/software platform for measuring and reporting left\n      ventricular (LV) function (volumes, strain, and ejection fraction [EF]), T1 myocardial\n      signal, and aortic pulse wave velocity (PWV).\n\n      II. To determine if pre- to 3 month post-anthracycline-based chemotherapy (Anth-bC) changes\n      in our MRI platform generated measures of LV volumes, EF, strain, myocardial T1, and aortic\n      PWV predict pre- to 24 month post-Anth-bC differences in these same parameters.\n\n      OUTLINE:\n\n      Patients undergo MRI scans for LV function, T1 myocardial signal, and aortic PWV at\n      baseline, 3 months, and 24 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Receiving >= 350 mg/m^2 of Anth-bC therapy, or a combination of Anth-bC (>= 250\n             mg/m^2) and subsequent paclitaxel or Herceptin\n\n          -  Ability to understand and the willingness to sign a written informed consent document\n\n        Exclusion Criteria:\n\n          -  Intracranial metal, pacemakers, defibrillators, functioning neurostimulator devices,\n             or other implanted electronic devices\n\n          -  Ferromagnetic cerebral aneurysm clips, or other intraorbital/intracranial metal\n\n          -  Allergy to gadolinium or other severe drug allergies\n\n          -  Unstable angina\n\n          -  Significant ventricular arrhythmias (> 20 premature ventricular contractions\n             [PVCs]/minute due to gating difficulty)\n\n          -  Acute myocardial infarction within 28 days\n\n          -  Atrial fibrillation with uncontrolled ventricular response\n\n          -  Moderate or severe aortic stenosis\n\n          -  Claustrophobia\n\n          -  Congestive heart failure (New York Heart Association [NYHA] class III or IV)\n\n          -  Significant valvular disease, or significant pulmonary disease requiring supplemental\n             oxygen therapy\n\n          -  Participants unwilling to complete the protocol (24 month duration)\n\n          -  Women who are pregnant\n\n          -  Patients unable or unwilling to provide informed consent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "22 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 11, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01719562", 
            "org_study_id": "CCCWFU 99112", 
            "secondary_id": [
                "NCI-2012-01613", 
                "P30CA012197"
            ]
        }, 
        "intervention": {
            "arm_group_label": "Diagnostic (MRI)", 
            "description": "Undergo MRI scans", 
            "intervention_name": "magnetic resonance imaging", 
            "intervention_type": "Procedure", 
            "other_name": [
                "MRI", 
                "NMR imaging", 
                "NMRI", 
                "nuclear magnetic resonance imaging"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 28, 2013", 
        "location": {
            "contact": {
                "email": "ghundley@wfubmc.edu", 
                "last_name": "William G. Hundley", 
                "phone": "336-716-6125"
            }, 
            "facility": {
                "address": {
                    "city": "Winston-Salem", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27157"
                }, 
                "name": "Comprehensive Cancer Center of Wake Forest University"
            }, 
            "investigator": {
                "last_name": "William G. Hundley", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Early Imaging Detection of Cardiovascular Injury After Cancer", 
        "overall_official": {
            "affiliation": "Comprehensive Cancer Center of Wake Forest University", 
            "last_name": "William Hundley", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "For the automation to be considered useful it should correlate highly with the manual results, exhibit a similar mean value and overall variability. 95% confidence intervals (CIs) of the difference between measures will be constructed and the upper and lower bounds of these intervals will be examined. The final diagnostic we will perform is to run F-tests to determine whether the variability from each measure is the same or different. 95% CIs will be examined for the ratio of the variance.", 
                "measure": "To correlate results of an automated MRI hardware/software platform for measuring left ventricular (LV) function with manual results.", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 months"
            }, 
            {
                "description": "Each patient is individually categorized as either having a persistent CV worsening or not depending on whether they exhibit a 20% worsening of their outcome by 3 months and that level of worsening persists to 24 months. We will examine paired t-tests for each time point for each measure to test whether measures are significantly worse at each time point. We will fit longitudinal models that examine all three time points (baseline, 3 and 24 months) simultaneously to determine whether there is a linear (or some other) function that can describe the decline in these subclinical CV MRI measures.", 
                "measure": "To test the ability of the pre- to post-anthracycline-based chemotherapy (Anth-bC) changes in our MRI platform generated measures of LV function to predict pre- to 24 month post-Anth-bC differences in LV function.", 
                "safety_issue": "No", 
                "time_frame": "From baseline to 24 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01719562"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Comprehensive Cancer Center of Wake Forest University", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Comprehensive Cancer Center of Wake Forest University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}